[{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Hepcidin","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Icotrokinra","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PN-943","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Hematology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rusfertide Analog","moa":"Hepcidin","graph1":"Hematology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Hepcidin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"PN-881","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"PN-232","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL-23 receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"}]

Find Clinical Drug Pipeline Developments & Deals by Protagonist Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.

                          Product Name : PTG-300

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 03, 2025

                          Lead Product(s) : Rusfertide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

                          Product Name : PN-881

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          November 21, 2024

                          Lead Product(s) : PN-881

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.

                          Product Name : PTG-300

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 26, 2024

                          Lead Product(s) : Rusfertide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : The collaboration supports PTG-300 (rusfertide) development for Polycythemia Vera, with the protagonist responsible for research and completing the Phase 3 trial and U.S. regulatory approval.

                          Product Name : PTG-300

                          Product Type : Peptide

                          Upfront Cash : $300.0 million

                          March 18, 2024

                          Lead Product(s) : Rusfertide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : The collaboration supports the development of PTG-300 (rusfertide) for Polycythemia Vera. The protagonist is responsible for completing the Phase 3 trial and U.S. regulatory approval.

                          Product Name : PTG-300

                          Product Type : Peptide

                          Upfront Cash : $300.0 million

                          January 31, 2024

                          Lead Product(s) : Rusfertide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.

                          Product Name : JNJ-2113

                          Product Type : Peptide

                          Upfront Cash : $50.0 million

                          December 13, 2023

                          Lead Product(s) : Icotrokinra

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Janssen Biotech

                          Deal Size : $987.5 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.

                          Product Name : JNJ-2113

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : Icotrokinra

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : The net proceeds intends to fund the continued clinical development and pre-commercialization activities associated with PTG-300 (rusfertide), an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.

                          Product Name : PTG-300

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          April 04, 2023

                          Lead Product(s) : Rusfertide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : J.P. Morgan

                          Deal Size : $100.0 million

                          Deal Type : Public Offering

                          blank

                          09

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : PTG-300 (rusfertide) is a hepcidin-mimetic that helps reduce iron availability to help achieve hematocrit control and decrease erythropoiesis in patients with polycythemia vera (PV) without the need for periodic therapeutic phlebotomy.

                          Product Name : PTG-300

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 15, 2023

                          Lead Product(s) : Rusfertide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : The collaboration aims for the co-development and commercialization of JNJ-2113, a novel, first and only oral IL-23 receptor antagonist peptide, in patients with moderate-to-severe psoriasis.

                          Product Name : JNJ-2113

                          Product Type : Peptide

                          Upfront Cash : $50.0 million

                          January 11, 2023

                          Lead Product(s) : Icotrokinra

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Janssen Biotech

                          Deal Size : $990.0 million

                          Deal Type : Collaboration

                          blank